Radiofrequency ablation of benign thyroid nodules does not affect thyroid function in patients with previous lobectomy.

Ha, Eun Ju; Baek, Jung Hwan; Lee, Jeong Hyun; Sung, Jin Yong; Lee, Ducky; Kim, Jae Kyun; Shong, Young Kee
Thyroid : official journal of the American Thyroid Association
2013Mar ; 23 ( 3 ) :289-93.
ÀúÀÚ »ó¼¼Á¤º¸
Ha, Eun Ju -
Baek, Jung Hwan -
Lee, Jeong Hyun -
Sung, Jin Yong -
Lee, Ducky -
Kim, Jae Kyun -
Shong, Young Kee -
ABSTRACT
BACKGROUND: Surgical management of symptomatic benign thyroid nodules in patients with previous lobectomy poses a dilemma for physicians. Radiofrequency (RF) ablation may provide a treatment option that avoids surgery and preserves thyroid function. We evaluated whether RF ablation of benign thyroid nodules affects thyroid function in patients with previous lobectomy.

METHODS: A total of 11 patients with 14 thyroid nodules were enrolled using the following criteria: (i) having a predominantly solid nodule; (ii) reporting pressure symptoms or cosmetic problems; (iii) cytological confirmation of benignancy; (iv) no malignant features detected using ultrasound; (v) serum thyroid hormone and thyrotropin (TSH) levels within normal limits; and (vi) refusal of or ineligibility for surgery. Thyroid function, nodule volumes, and clinical concerns were evaluated before RF ablation and during follow-up after RF ablation.

RESULTS: The mean follow-up duration after RF ablation was 43.7±30.7 months (range=7-92 months). The mean nodule volume was 9.7 mL (0.9-57.6 mL) before the procedure, and was significantly decreased at the last follow-up (p<0.001) with a mean volume reduction rate of 87.2%. The mean symptom score (p=0.003) and cosmetic score (p=0.003) were both significantly decreased at the last follow-up. Levels of TSH, free thyroxine, and triiodothyronine were not significantly different prior to treatment and at the last follow-up (p>0.05), and remained normal in all patients.

CONCLUSIONS: In patients with previous lobectomy, RF ablation should be considered as a first-line treatment for symptomatic benign thyroid nodules to preserve thyroid function.
na
MESH
Adult, Catheter Ablation/*methods, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Thyroid Gland/physiology/radiation effects/*surgery, Thyroid Hormones/blood, Thyroid Nodule/*radiotherapy/*surgery, Thyroidectomy/methods, Thyrotropin/blood, Treatment Outcome
¸µÅ©

ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
In patients with previous lobectomy, RFA should be considered as a first-line treatment for symptomatic benign thyroid nodules to preserve thyroid function.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
10.1089/thy.2012.0171.
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå